Brief: Palatin Tech Announces First Patient Enrolled In Dry Eye Disease Phase 2 Clinical Trial With Pl9643
19/02/2020 12:42
Feb 19 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN TECHNOLOGIES, INC. ANNOUNCES FIRST PATIENT
ENROLLED IN
DRY EYE DISEASE PHASE 2 CLINICAL TRIAL WITH PL9643
* PALATIN TECHNOLOGIES INC - DRY EYE DISEASE PHASE 2
CLINICAL
TRIAL STUDY RESULTS EXPECTED Q4 2020
Source text for Eikon: ID:nPn21bwvca
Further company coverage: PTN.A
(Reuters.Briefs@thomsonreuters.com)
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity